BRIDGET WILLIAMS: Open Payments
NPI 1376134668 · SHERIDAN, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$355 in 21 payments from 12 companies in 2025. Trend: 2023 $364 · 2024 $344 · 2025 $355
Food & beverage: $355
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $107 |
| AstraZeneca Pharmaceuticals LP | 4 | $65 |
| Lilly USA, LLC | 2 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $17 |
| Novo Nordisk Inc | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| PFIZER INC. | 1 | $16 |
Products named: UBRELVY, AIRSUPRA, VRAYLAR, QULIPTA, HETLIOZ, CAPLYTA, BREZTRI, GEMTESA.
Industry payments across AR — which companies pay providers there.
